Shirkadda dawooyinka bayoolojiga ee fadhigeedu yahay Mareykanka, Gilead Sciences, ayaa Isniintii ku dhawaaqday inay gashay heshiis kama dambays ah oo ay ku iibsanayso shirkadda horumarisa dawooyinka kansarka ee Arcellx, qiimihiisuna gaarayo ku dhowaad $7.8 bilyan.
Heshiiska waxaa ku jira $115 oo lacago caddaan ah halkii saamiba, iyo xuquuq qiime ku xiran (contingent value right) oo dhan $5 halkii saamiba.
Iibsashadan ayaa ujeedadeedu tahay in la kordhiyo awoodda muddada-dheer ee anito-cel, oo ah daaweyn unugyo ku saleysan oo wali tijaabo ah (investigational cell therapy) looguna talagalay bukaanada qaba multiple myeloma (nooc kansarka dhiigga ah).
Kite, oo ah shirkad hoos timaada Gilead, ayaa hore ula shaqeyneysay Arcellx si wadajir ah loogu horumariyo loona suuq-geeyo daaweyntan cusub ee difaaca jirka ku saleysan (immunotherapy).
Guddoomiyaha iyo Maamulaha Guud ee Gilead, Daniel O’Day, ayaa sheegay in heshiisku ka tarjumayo kalsoonida shirkaddu ku qabto awoodda daaweyntan cusub ee ka caawin karta bukaanada kansarka.
US Food and Drug Administration (FDA) ayaa hore u aqbashay codsiga oggolaanshaha shatiga bayoolojiga (biologics license application) ee anito-cel, iyadoo la filayo inay go’aan ka gaarto 23-ka Diseembar 2026.
Guddiyada agaasimayaasha ee labada shirkadood ayaa ansixiyay heshiiska, kaas oo la filayo in la soo gabagabeeyo rubuca labaad ee sannadka 2026.
Ka hor ku dhawaaqista isku-darka, Gilead waxay hore u lahayd qiyaastii 11.5% saamiyada caadiga ah ee Arcellx.